NEO PanTracer Tissue (formerly Neo Comprehensive - Solid Tumor)

PanTracer Tissue is a broad, next‑generation sequencing panel for pan‑solid tumor indications. The assay detects single nucleotide variants (SNV), insertions/deletions (InDels), copy number variants (CNV), and RNA fusions and splice variants across a comprehensive gene set, plus microsatellite instability (MSI) and tumor mutational burden (TMB).

NGS (517 total genes: DNA analysis across 517 genes; RNA fusion/splice analysis across 55 of these genes)

Immunotherapy Markers: MSI, TMB
* MSI-high is defined as ≥20% of loci showing instability; microsatellite-stable (MSS) is defined as <20% of loci showing instability.
* TMB-high is defined as ≥10.0 mutations per megabase (mut/Mb); TMB-low is defined as <10.0 mut/Mb

Legacy Test information:
As of May 29, 2025, this test serves as replacement for the following test:
* Neo Comprehensive – Solid Tumor